[HTML][HTML] The day-to-day practice of MMR and MSI assessment in colorectal adenocarcinoma: what we know and what we still need to explore

P Parente, F Grillo, A Vanoli, MC Macciomei… - Digestive …, 2023 - karger.com
Background: The DNA mismatch repair (MMR) system is a highly preserved protein complex
recognizing short insertions, short deletions, and single base mismatches during DNA …

The role of the pathologist in the next-generation era of tumor molecular characterization

V Angerilli, F Galuppini, F Pagni, N Fusco, U Malapelle… - Diagnostics, 2021 - mdpi.com
Current pathology practice is being shaped by the increasing complexity of modern
medicine, in particular of precision oncology, and major technological advances. In the “next …

Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas

A Pellino, S Brignola, E Riello, M Niero… - Journal of Personalized …, 2021 - mdpi.com
Simple Summary Claudin-18 is a tight junction protein expressed in various cancer types
including gastric and gastroesophageal junction cancer. The claudin-18.2 isoform …

PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application

L Mastracci, F Grillo, P Parente, I Gullo… - …, 2022 - pmc.ncbi.nlm.nih.gov
Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical
benefit in many solid cancer types, including gastrointestinal malignancies. However, it has …

[HTML][HTML] Evaluation of micro satellite instability and mismatch repair status in different solid tumors: a multicenter analysis in a real world setting

U Malapelle, P Parente, F Pepe, C De Luca, P Pisapia… - Cells, 2021 - mdpi.com
Immune-checkpoint inhibitors (ICIs) play a key role in the treatment of advanced stage
colorectal cancer (CRC) patients featuring a deficient DNA mismatch repair (dMMR) system …

[HTML][HTML] Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study

M Rizzato, S Brignola, G Munari, M Gatti… - European Journal of …, 2022 - Elsevier
Aim FGFR2 rearrangements have been identified as a novel therapeutic target of biliary tract
cancer (BTC). However, reliable prevalence estimates of this molecular alteration and its …

[HTML][HTML] FFPE-based NGS approaches into clinical practice: the limits of glory from a pathologist viewpoint

F Cappello, V Angerilli, G Munari, C Ceccon… - Journal of Personalized …, 2022 - mdpi.com
The introduction of next-generation sequencing (NGS) in the molecular diagnostic
armamentarium is deeply changing pathology practice and laboratory frameworks. NGS …

HER2-low in gastro-oesophageal adenocarcinoma: A real-world pathological perspective

V Angerilli, P Parente, M Campora, C Ugolini… - Journal of Clinical …, 2023 - jcp.bmj.com
Aims In the DESTINY-Gastric01 trial, a novel HER2-targeted antibody-drug conjugate
trastuzumab deruxtecan proved to be effective in HER2-low gastro-oesophageal …

Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens

F Grillo, M Paudice, A Gambella, S Bozzano… - Histochemistry and Cell …, 2023 - Springer
Mismatch repair (MMR) testing on all new cases of colorectal cancer (CRC) has customarily
been preferably performed on surgical specimens, as more tissue is available; however …

[HTML][HTML] mRNA vaccine in gastrointestinal tumors: Immunomodulatory effects and immunotherapy

A Zhang, Q Ji, X Sheng, H Wu - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Gastrointestinal tumors remain a significant healthcare burden worldwide, necessitating the
development of innovative therapeutic strategies. mRNA vaccines have emerged as a …